Arbutus Biopharma (ABUS) Other Operating Expenses (2013 - 2026)

Arbutus Biopharma has reported Other Operating Expenses for 13 years, with the latest figure at $209000.0 in Q1 2026.

• Quarterly Other Operating Expenses fell 30.1% year-over-year to $209000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$14.2 million (down 615.85% YoY) and the FY2025 annual result came in at $674000.0, changed N/A from the prior year.
• Other Operating Expenses climbed to $209000.0 in Q1 2026 per ABUS's latest filing, from -$2.7 million in the prior quarter.
• Over five years, Other Operating Expenses peaked at $1.9 million in Q4 2024 and troughed at -$12.0 million in Q2 2025.
• A 5-year average of -$525235.3 and a median of $211000.0 in 2024 frame the typical range for Other Operating Expenses.
• The sharpest annual moves came in 2022 and 2025: Other Operating Expenses soared 733.68% in 2022, then sank 5775.36% in 2025.
• Over 5 years, Other Operating Expenses stood at $1.6 million in 2022, then plunged by 85.89% to $227000.0 in 2023, then surged by 732.6% to $1.9 million in 2024, then plunged by 240.58% to -$2.7 million in 2025, then soared by 107.87% to $209000.0 in 2026.
• According to Business Quant data, Other Operating Expenses over the past three periods registered $209000.0, -$2.7 million, and $268000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.